CBMG stock forecast
Our latest prediction for Cellular Biomedicine Group, Inc.'s stock price was made on the Dec. 22, 2017 when the stock price was at 11.10$.
In the short term (2weeks), CBMG's stock price should outperform the market by 2.36%. During that period the price should oscillate between -6.54% and +9.37%.
In the medium term (3months), CBMG's stock price should outperform the market by 3.03%. During that period the price should oscillate between -16.07% and +27.59%.Get email alerts
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. The company was founded in 2009 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.24$ per share.
The book value per share is 4.18$
Three months stock forecastDec. 22, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|